Page 32 - Memora anual Fundación CIEN 2017

(Cajal Blue Brain) integrated by scientists from the Technical University of Madrid and CSIC. He belongs
to CIBERNED and collaborates actively with the CIEN Foundation.
• Mr. Miguel Medina Padilla. Doctor in Biochemistry and Molecular Biology from the Autonomous
University of Madrid. Deputy Scientific Director of CIBERNED.
• Mr. José Ramón Naranjo Orovio. PhD in Pharmacy from the Complutense University of Madrid.
Neurobiologist at the National Center for Biotechnology (CSIC). He belongs to CIBERNED and
collaborates actively with the CIEN Foundation..
• Mr. Fernando Rodríguez Artalejo. Doctor in Medicine and Surgery from the Autonomous University of
Madrid. Professor of Preventive Medicine and Public Health at the Autonomous University of Madrid.

▄▀ 1.7. Vision assessments of the volunteers, their biological sam-
ples and the neuroimaging studies carried out inte-
The Vallecas Project is the main research project grates with that of other national and international
being conducted at the CIEN Foundation, both in cohorts such as the European Medical Information
terms of resources employed as well as in terms of its Framework (EMIF), which will significantly increase
social impact. At the end of 2013 the project con- the potential of each of them as well as the Valle-
cluded the recruitment and the phase of initial eva- cas Project itself.
luation of the volunteers. The following figure shows
the status of the clinical evaluations carried out up to In addition, a new agreement is being worked out
December 31, 2017 (the exact figures can be loo- with the Queen Sofia Foundation in order to establish
ked up in section 4.3.8 of this report). During the first the framework for collaboration to continue con-
half of 2017, the fourth, fifth and sixth visits have been ducting research aimed at identifying individuals at
performed simultaneously, and the seventh study greater risk of developing Alzheimer's dementia in
visit has begun. the second phase of the project called "Vallecas 2
Project. Early detection of Alzheimer's disease. Risk
As the project progresses, a large volume of increa- and protection factors". This new agreement will
singly rich and relevant information is generated on allow us to extend the current project activities and
the most initial phases of cognitive impairment in update the objectives based on the experience ac-
those subjects who develop it, as well as on the bio- cumulated in recent years as well as maintain a co-
markers (clinical, biochemical and neuroimaging) hort of volunteers whose added value in terms of
most suitable for its characterization and identifica- quantity and quality of data, along with its scientific
tion of the population at greater risk of developing it. relevance, increases every year, making it a refe-
In addition to continuing to present our preliminary rence cohort in the study of the factors that deter-
results in different congresses and scientific mee- mine the onset of mild cognitive impairment and
tings, the commitment to publish the results genera- Alzheimer's type dementia in the elderly.
ted from the longitudinal analysis of the Vallecas
project in international scientific journals of the gre- Besides the Vallecas Project, the studies with the pa-
atest possible impact is maintained (see section tients from the residence will continue in the Queen
6.2.1.). Sofia Foundation Alzheimer Center and the CIEN
Foundation to study dementia in its moderate and
In recent months, we have initiated the necessary advanced stages. As indicated, this longitudinal
contacts so that the information obtained from the study, initiated in 2007, aims to monitor and follow up

CIEN Foundation Annual Report 2017 / 32